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In  April  2009,  the  World  Health  Organization  (WHO)  reported  the  emergence  of a  new  inﬂuenza  (H1N1)
virus  which  led  to the  ﬁrst pandemic  declaration  of  the  21st  century.  Most  countries  in Latin  America
and  the  Caribbean  (LAC)  had  a national  preparedness  plan  in  place  at this  time;  however,  the  vaccina-
tion  component  of  such  plans  was  largely  undeveloped.  Nevertheless,  countries  were  able  to  capitalize
on  the  infrastructure  of  their  immunization  programs  and  widespread  experience  utilizing  the  sea-
sonal  inﬂuenza  vaccine  to  prepare  rapidly,  developing  H1N1  vaccination  plans  targeting  individuals  with
chronic  disease,  pregnant  women  and  health  care  workers,  among  others.  In  LAC  vaccine  was  acquired
through  three  mechanisms:  the  Pan American  Health  Organization’s  Revolving  Fund,  direct  manufacturer
purchase,  and  WHO  donations.  Vaccine  access  was  not  equitable  both  in quantity  of vaccine  available  and
timeless  of  vaccine  availability.  As  of  December  2010,  an  estimated  145  million  doses  had  been  admin-
istered  in  LAC.  Despite  high  regional  coverage,  there  were  large  variations  in  coverage  at  the  national
level;  pregnant  women  had  the  lowest  coverage,  despite  their  high  risk  for  morbidity  and  mortality.
The  number  of  severe  adverse  events  reported  in  LAC  was  similar  to  those  expected  with  the  seasonal
inﬂuenza  vaccine.  Risk  communication  was  one  of the  key  challenges  countries  faced,  mainly  due to  con-
cerns  and  misinformation  spread  regarding  vaccine  safety.  Countries  and  the  international  community
need  to learn  from  the  experiences  gained  during  H1N1  vaccination  in  order  to be  better  prepared  for
alth O     
the  next  pandemic.
© 2011 Pan American He
. Introduction
On 25 April 2009 the World Health Organization (WHO)
eported the emergence of a new inﬂuenza (H1N1) virus detected
n North America [1]. This virus rapidly disseminated globally
eading to the declaration of the ﬁrst pandemic of the twenty-ﬁrst
entury [2].
While  the pandemic had moderate severity [3,4], speciﬁc risk
roups appeared to have increased risk of morbidity and mortality,
ncluding pregnant women and individuals with chronic medical
onditions [5–9].
Vaccination is the most effective preventive measure against
nﬂuenza [10,11], but the time required for inﬂuenza vaccine
roduction meant that countries had to mitigate the ﬁrst pan-
emic wave without a vaccine. A strategy based on antiviral
se, public health measures and social distancing was  used to
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0037-2895, USA. Tel.: +1 202 974 3706; fax: +1 202 974 3635.
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s underrganization. Published by Elsevier Ltd.
limit disease transmission and population impact [12]. Early anal-
ysis of vaccine production capacity highlighted that pandemic
inﬂuenza (H1N1) vaccine would be scarce for those countries
without pre-existing purchase agreements with manufacturers
[4,13]. In spite of concerns about vaccine access, countries in Latin
America and the Caribbean (LAC), with historically strong vaccina-
tion programs [14], began preparations for upcoming vaccination
campaigns.
The Pan American Health Organization (PAHO) serves as the
WHO Regional Ofﬁce for the Americas and provides technical assis-
tance to countries and territories in the Region [14]. During the
pandemic, PAHO provided technical cooperation to countries to
mitigate the pandemic impact and served as a Regional platform
for information sharing [14].
The objective of this article is to describe the process of prepa-
ration, procurement, and use of the pandemic inﬂuenza (H1N1)
vaccine in LAC, and to discuss the lessons learned from this expe-
rience.
Open access under CC BY-NC-ND license.   2. Data sources
We  examined data sent from Member States to PAHO includ-
ing population targeted for pandemic (H1N1) vaccination, vaccine
    CC BY-NC-ND license.
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ource, campaign dates, coverage by target group, and the number
nd classiﬁcation of events supposedly associated with vaccines
nd immunization (ESAVI).
Other information sources included pandemic (H1N1) vaccine
rocurement records from PAHO’s Revolving Fund (RF) and WHO
eports on pandemic inﬂuenza (H1N1) vaccine donations. The RF is
 mechanism for bulk purchase of vaccines and immunization sup-
lies, managed by PAHO since 1979. PAHO consolidates vaccine
rders from participating Member States and conducts interna-
ional bids open to vaccine manufacturers on their behalf [15,16].
e gathered any missing information through ad hoc phone calls
ith countries.
.  Pandemic preparation activities
WHO recommends the use of seasonal inﬂuenza vaccine as
 key strategy for pandemic preparedness [17]. Though the sea-
onal vaccine is unlikely to protect against a pandemic inﬂuenza
irus, the use of this vaccine helps countries gain experience vac-
inating otherwise non-traditional population groups. It is also
hought to reduce the probability of recombination of inﬂuenza
irus strains. Furthermore, the heightened demand for seasonal
accine increases global inﬂuenza vaccine production capacity
17,18].
Beginning in 2004, there was a marked uptake of the seasonal
nﬂuenza vaccine in LAC [19]. As of December 2008, 35 of 45 LAC
ountries and territories (excluding the French Departments), had
ntroduced seasonal inﬂuenza vaccine in their national vaccination
rograms [19].
When  cases of pandemic inﬂuenza (H1N1) virus were ﬁrst iden-
iﬁed in spring 2009 most LAC countries had a national pandemic
reparedness plan in place [20] which focused mostly on prepa-
ation of health services and virus surveillance; the vaccination
omponent of such plans remained largely undeveloped, as vac-
ine was not expected to be available during the ﬁrst pandemic
ave [18,21,22].
When the pandemic inﬂuenza (H1N1) virus surfaced, PAHO
eveloped a regional plan to provide technical cooperation in vacci-
ation to LAC. This plan included three main pillars: (1) immediate
upport for seasonal inﬂuenza vaccination in countries not yet
dministering it; (2) technical cooperation to assist LAC countries
n elaborating national pandemic vaccination plans of action; and
3) support in pandemic (H1N1) vaccine acquisition [23].
In  May  2009, PAHO mobilized resources to support the use of
easonal inﬂuenza vaccine in nine remaining countries and territo-
ies in the Region yet to have introduced the vaccine2.
In  July 2009, WHO’s Strategic Advisory Group of Experts (SAGE)
ade their ﬁrst recommendations on pandemic vaccination tar-
et groups [9]. One month later, PAHO’s Technical Advisory Group
TAG) endorsed these recommendations, but due to expected vac-
ine scarcity, TAG emphasized the vaccination of individuals with
hronic medical conditions and pregnant women in order to reduce
orbi-mortality. TAG also promoted vaccinating health-care work-
rs to protect critical health infrastructure [24]. In the event that
ore vaccine became available, TAG recommended expanding tar-
et populations, vaccinating groups such as school children to
educe community transmission [9,24].
PAHO prepared comprehensive technical guidelines which
ncluded topics such as deﬁning target populations; vaccination
trategies; planning and micro-planning; vaccination safety,
ncluding regulatory considerations, ESAVI surveillance, risk
ommunication and crisis planning; vaccine deployment; and
2 Aruba, Bolivia, Dominica, Guyana, Haiti, St Kitts and Nevis, St Maarten, St Vincent
nd  the Grenadines, and Suriname.cine 30 (2012) 916– 921 917
vaccination waste management [23]. PAHO also developed sepa-
rate expanded guidelines on ESAVI surveillance and management
[25]. Country training workshops were conducted between
October and November 2009.
4. Vaccine procurement and access to vaccines
4.1. Vaccine procurement
Pandemic  inﬂuenza (H1N1) vaccine was acquired in LAC
through three mechanisms: (1) purchase through PAHO’s Revolv-
ing Fund (RF); (2) direct purchase from vaccine manufacturers;
and (3) WHO  donation. Some countries used more than one
mechanism.
In September 2009, the RF opened a bid solicitation for
approximately 400 million doses of pandemic inﬂuenza (H1N1)
vaccine. This amount was  based on a prior PAHO survey to
Member States and not yet knowing whether one or two doses
would be required. Sub-regional economic integration systems,
such as the Union of South American Nations (UNASUR), sup-
ported countries’ use of the RF for pandemic inﬂuenza (H1N1)
vaccine purchase based on the beneﬁts of collective group
negotiation [15,26].
Approximately 20.5 million doses of pandemic (H1N1) vaccine
from different manufacturers were procured on behalf of 24 LAC
countries/territories, including 16.9 million doses of un-adjuvanted
vaccines (82.3%) and 3.6 million (17.7%) adjuvanted doses. The ﬁnal
number resulted from several factors, including evidence that only
one dose was  needed for protection among persons aged ≥10 years,
changing perceptions regarding the pandemic’s severity, and the
fact that not all the vaccine offered met  the Fund’s requirements.
Argentina, Brazil, and Mexico purchased approximately 151
million doses of H1N1 vaccine directly from manufacturers. This
was in addition to the approximately 174 million doses acquired
by Canada and the United States.
As part of their response to the Inﬂuenza (H1N1) pandemic,
WHO coordinated a global effort to donate pandemic inﬂuenza
(H1N1) vaccine to 95 eligible countries. Ten LAC countries (Bolivia,
Cuba, El Salvador, Guatemala, Guyana, Haiti, Honduras, Nicaragua,
Paraguay, and Suriname) were originally eligible to receive donated
vaccine. Chile was later added to the list after a devastating earth-
quake in February 2010 [27].
To receive donated vaccine, countries had to present a national
vaccination plan specifying vaccine target populations to be
approved by regional WHO  ofﬁces and headquarters. Additionally,
countries had to demonstrate that the vaccine had been approved
by national regulatory authorities and accept the liability for any
ESAVI.
As of September 2010, approximately 10 million donated doses
had been received; 6.8 million (67.3%) contained adjuvant and 3.3
million (32.7%) were un-adjuvanted. Haiti was  eligible to receive
one million doses, but a ﬁnal decision as to whether to accept this
donation was  not received from the country.
Bolivia, Chile and Honduras purchased vaccine through the
RF and received WHO  donated vaccine. Brazil purchased vaccine
directly from the manufacturer, as well as through the RF, and Suri-
name received WHO  donated vaccine and also procured vaccine
through the government of the Netherlands.
4.2. Vaccine accessLAC  countries had access to H1N1 vaccine; however it was  far
from equitable, both in the quantity of vaccine available as well as in
the timeliness of vaccine availability. Vaccine arrived in most coun-
tries between January and May  2010, generally past the main peak
918 A.M.  Ropero-Álvarez et al. / Vaccine 30 (2012) 916– 921
Table 1
Implementation of pandemic (H1N1) vaccination campaigns in LAC.
Countries and territories Doses administereda Total population coverage Prioritized risk groups
Health personnel and
essential  services
Pregnant women Chronic diseases Others
Anguilla – – – – – –
Argentina 8,258,009 20.7%  104.7% 101.4% 132.5% 116.2%
Bahamas  5006 1.5% 18.0% 18.6% 15.8% –
Barbados 4360  1.7% 64.2% 3.3% 11.5% –
Belize  10,146 3.4% – – – –
Bermuda  1053 1.6% – – – –
Bolivia  1,249,049 12.9% 67.1% 32.0% 69.2% 144.7%
Brazil 92,000,000 47.9% 120.1% 77.1% 163.2% 81.8%
Cayman  Islands 2318 4.8%  1.8% 5.6% 0.0% 5.0%
Chile  3,084,124 18.4% 107.0% 54.4% 80.1% 77.3%
Colombia  2,037,301 4.5% 53.4% 58.5% 101.3% 59.5%
Costa  Rica 180,000 4.0% – – – –
Cuba  1,123,526 10.0% 101.8% 100.7% 98.8% 100.7%
Ecuador  973,480 7.2% 101.7% 80.8% 92.8% 104.4%
El  Salvador 1,690,101 27.6% 186.0% 44.7% – 114.6%
Grenada  396 0.4% 5.1% 0.4% 1.1% –
Guatemala  1,295,742 9.6% 81.0% 58.0% 67.0% 100.0%
Guyana 170,601 22.4%  – – – –
Hondurasb 1,810,783 20.0% 104.0% 75.0% 136.0% 86.0%
Mexico 26,903,232 24.8% 94.9% 71.7% 101.9% 82.2%
Montserrat  1245 24.9% – – – –
Nicaragua  251,759 4.4% 91.3% 88.1% 37.5% 15.7%
Panama  254,286 7.5% 50.1% 32.1% 374.8% 85.3%
Paraguay  1,087,661 17.4% 85.5% 37.3% 77.1% 103.3%
Peru 2,237,053 7.8% 42.5% 9.1% 24.5% 249.7%
Suriname  24,674 4.8% 23.4% 4.5% 10.4% –
Trinidad  and Tobago 23,985  1.8% 57.0% 0.7% – –
Turks  and Caicos Islands 2837 12.9% 25.9% 6.3% 12.7% 57.4%
Uruguay  538,057 16.1% – – – –
Venezuelac 500,000 – – – – –
Totald 145,220,802 28.0%
Source: Country and territory reports to PAHO, FCH/IM.
a Data as of December 2010.
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c Doses purchased.
d The total number of administered doses does not include doses purchased by V
f pandemic inﬂuenza activity [28]. For the 19 countries and terri-
ories with complete information available, the interval between
accine reception and initiation of vaccination activities ranged
rom 1 to 39 days, median of 11 days.
The ﬁrst two countries in the Western Hemisphere to have
ccess to the pandemic inﬂuenza (H1N1) vaccine were Canada and
nited States in October 2009 (both purchased vaccine directly
rom manufacturer). Argentina, Brazil and Mexico received vac-
ine, also through direct purchase, from December 2009 to April
010. Brazil and Mexico had previous agreements with manufac-
urers for the transfer of technology related to inﬂuenza vaccine
roduction. Argentina had also developed a public–private agree-
ent with a manufacturer. Countries buying vaccines through the
F received shipments from January 2010 to May  2010, with the
xception of Trinidad and Tobago, which received 80,000 doses in
ovember 2009. Recipient countries of WHO  donation began to
eceive vaccine in March–June 2010 (Fig. 1).
Canada and the United States procured enough vaccine to cover
p to 50% of their total population. Argentina, Brazil and Mexico
urchased vaccine to cover, on average, 44% of their populations.
ountries that procured vaccine exclusively from the RF covered
pproximately 5% of their total population. Recipient countries of
HO  donated vaccine were able to cover approximately 13% of
heir respective populations (Fig. 1).. Implementation of vaccination campaigns
LAC countries established speciﬁc vaccination goals for high
isk groups, targeting approximately 147 million people. As ofela.
December 2010, an estimated 145 million doses had been admin-
istered in LAC, representing approximately a 99% completion of
the pre-established goal. Despite this high regional coverage, large
variations by country in vaccination coverage of high risk groups
existed (Table 1).
Reported  coverage of pre-established target populations in LAC
ranged from 1% to greater than 100%. Fourteen countries and
one territory (Montserrat) achieved target population coverage
of ≥70%. Argentina, Brazil, Colombia, Cuba, Ecuador, El Salvador,
Guatemala and Mexico reached ≥95% of their target populations.
Not  all countries reported disaggregated vaccine coverage data
of individual prioritized risk groups. The highest coverage reported
was for targeted individuals with chronic medical conditions, at
an average of 110%, followed by health personnel and essential
services, averaging 100% coverage. The lowest vaccination cov-
erage was  reported for pregnant women, averaging 67% of the
pre-established goal. For other risk groups, 17 countries reported
coverage ranging from 5% to greater than 100% (Table 1).
Many  LAC countries encountered difﬁculties vaccinating preg-
nant women, despite their high risk of inﬂuenza (H1N1) morbidity
and mortality, especially in the 2nd and 3rd trimester of pregnancy,
and in the ﬁrst two  weeks post partum [8,29].
6. ESAVI surveillanceMost  LAC countries have developed ESAVI surveillance systems
as part of their monitoring of regular vaccination activities. With
pandemic inﬂuenza vaccination, special focus was given to clini-
cal events such as Guillain-Barré Syndrome (GBS) and anaphylaxis
A.M. Ropero-Álvarez et al. / Vaccine 30 (2012) 916– 921 919
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reporting coverage >100%, as original denominators were never
adjusted.
Table 2
Available diagnoses of reported ESAVI cases. Pandemic inﬂuenza (H1N1) vaccina-
tion,  LAC 2010.
N % Severe ESAVI Reported cases per
million  doses
ESAVI reporteda 13,621 94.59
Fever  1466 – 10.18
Severe  ESAVI 846 100.0% 5.88
GBS  101 11.9% 0.70
Seizuresb 27 3.2% 0.19
Other  neurological events 19 2.2% 0.13
Pneumonia/BCP/Bronchitis 8 0.9% 0.06
Anaphylaxis  72 8.5% 0.50ig. 1. Differential access to pandemic (H1N1) vaccine in the Americas, 2009–201
overed by one dose of the vaccine acquired in each country category.
ource: Country and territory reports to PAHO, FCH/IM.
25]; updated alerts on vaccine safety were also sent periodically
o countries to increase awareness of other possible ESAVI [30,31].
As of December 2010, the types of ESAVI following pandemic
H1N1) vaccination in LAC were similar to what would be expected
ith the seasonal inﬂuenza vaccine [10] and no deaths were iden-
iﬁed as being causally related to the vaccine. The data presented
re still preliminary, as countries’ are ﬁnalizing the classiﬁcation
f cases. A total of 13,621 ESAVI cases were reported to PAHO,
46 (6.2%) of them were classiﬁed by countries as severe (rate of
.9 severe ESAVI per million doses administered). Of these, 389
ases were classiﬁed by countries as being related to vaccina-
ion itself (rate of 2.7 ESAVI per million doses administered) and
0 ESAVI were deﬁned as programmatic errors (errors in vaccine
torage, preparation, handling or administration) [32]. The rate of
BS reported (0.7 reported per million doses administered) was
imilar to that found in seasonal inﬂuenza vaccination and pre-
iminary pandemic (H1N1) vaccination in the United States [33]
Table 2). Analyses in LAC have shown a baseline rate of 0.82 GBS
ases per 100,000 children aged less than 15 years [34]. There were
2 cases of anaphylaxis that were classiﬁed as related to vaccina-
ion; rate of 0.5 per million doses. Twenty-seven seizures (both
ebrile and non-febrile) were reported; rate of 0.19 per million
oses (Table 2).
.  Risk communication
Risk  communication was a key component throughout the
lanning and implementation of pandemic inﬂuenza (H1N1) vacci-
ation campaigns. PAHO’s guidelines included risk communication
trategies for countries to prepare for anticipated vaccine shortages
nd to focus their vaccination efforts on speciﬁc high risk groups
35]
As the pandemic evolved and rumors related to vaccine safety
merged, risk communication again became critical to promote the
mportance of pandemic inﬂuenza vaccine as a safe means to reduce
orbidity and mortality among high risk groups. A group of experts
n risk communication was convened to support selected countries
n their social communication and crisis management activities
Bolivia, El Salvador, Guatemala, Paraguay, and Suriname).onth of vaccine arrival. Shaded areas represent the percentage of the population
8. Lessons learned
8.1.  Data availability and sharing
Countries faced challenges in the accurate estimation of some
high risk groups to be vaccinated during campaigns. Many of
the target populations for pandemic inﬂuenza (H1N1) vaccination
were not traditionally targeted by immunization programs, such
as individuals with chronic medical conditions. In many countries,
systematic information for campaign planning was not available.
Population estimates for people with chronic conditions also varied
greatly across LAC, and denominators were generally underesti-
mated, resulting in many countries reporting coverage well over
100%. Deﬁning the order of priority of different chronic health con-
ditions was  another challenge which will be important to consider
during future pandemic planning.
Many countries initially made conservative estimates of
health care workers and planned to vaccinate mainly ﬁrst
responders. However, during the implementation of vaccination
campaigns, as more vaccine became available, additional health
care workers were often vaccinated, resulting in some countriesOther  severe events 619 73.2% 4.30
Source: Country and territory reports to PAHO, FCH/IM.
a Data as of December 2010 and based on reported cases, not conﬁrmed cases.
b Both febrile and non-febrile seizures.
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PAHO’s weekly reporting of the advances in national pandemic
nﬂuenza (H1N1) vaccination and reported ESAVI served to mon-
tor progress and disseminate information to interested parties.
his information sharing was only achieved through diligent and
oluntary country reporting. It would be necessary to formalize
uch regular reporting as a standard practice for the common good
uring future situations involving mass vaccination campaigns.
.2.  Pandemic preparation activities
The experience with pandemic inﬂuenza (H1N1) revealed the
mportance of including immunization as an integral part of pan-
emic planning. Despite expected delays in the availability of a
ovel inﬂuenza vaccine, countries would beneﬁt from having gen-
ral pre-established pandemic inﬂuenza operational and logistical
rotocols for vaccination. Such protocols can be adapted to consider
eveloping epidemiological information and in consultation with
dvisory groups, thus limiting some of the crucial decision-making
eeded in the midst of an emergency.
.3. Vaccine procurement and access to vaccines
Vaccine procurement and access in the Americas was  differ-
ntial and not equitable. The ﬁrst LAC countries to have access
o pandemic vaccine were those with pre-existing agreements
ith manufacturers. Regional or sub-regional efforts should be
ndertaken to enhance and extend current transfer of technology
greements for vaccine production in LAC.
PAHO’s RF played a key role in providing countries and territo-
ies, especially small ones, access to the vaccine.
The vaccine donation coordinated through WHO  was an interna-
ional diplomatic effort aiming to provide vaccine to those countries
ith less economic resources. Unfortunately, the donation process
roved to be lengthy, resulting in recipient countries being the last
o receive vaccine in LAC. Efforts to streamline future donation pro-
esses are necessary to ensure the timeliness and equity of such
ndeavors.
.4. Implementation of vaccination campaigns
Many LAC countries successfully implemented pandemic vacci-
ation campaigns, making use of the current infrastructure of the
ational immunization programs. They reached, on average, 99% of
heir pre-deﬁned high risk target populations. However, countries
ad to face multiple technical and logistical challenges, including
ultiple vaccine presentations, vaccine with and without adjuvant,
ultiple vaccine shipments due to ongoing production, and non-
raditional target groups. Clear guidelines and training workshops
onducted prior to vaccine arrival were critical for capacity building
f health-care workers to help them manage said challenges.
Pregnant women had the lowest pandemic inﬂuenza (H1N1)
accine coverage. In some countries health care professionals were
eluctant to recommend the vaccine. This issue highlights the
eed to enhance health-care worker training, increase the partic-
pation of scientiﬁc societies of obstetricians and gynecologists,
nd strengthen social communication regarding the beneﬁts of
nﬂuenza vaccination for pregnant women. These lessons can also
e applied to annual seasonal inﬂuenza vaccination.
Given the magnitude of vaccination activities in LAC and the
ommitment of countries to such an effort, it is important to assess
he impact of this investment in the reduction of inﬂuenza dis-
ase burden. Estimations of the impact of vaccination are underway
n selected countries and have presented a series of challenges,
ncluding the absence of serosurveys conducted prior to vaccine
ntroduction, and a lack of surveillance data stratiﬁed by vac-
ine target groups. These challenges and lessons learned fromcine 30 (2012) 916– 921
attempting  to measure the impact of pandemic inﬂuenza (H1N1)
vaccination should also be considered for measuring the impact of
seasonal inﬂuenza vaccine use and when planning vaccination in
the event of a future pandemic.
8.5.  ESAVI surveillance
All  pandemic vaccines used in LAC were well tolerated and
elicited mainly mild or moderate adverse reactions; surveillance
efforts did not ﬁnd signs of an increased risk of severe ESAVI, when
compared with seasonal inﬂuenza vaccination. These data have
several limitations, principally that most ESAVI surveillance sys-
tems in LAC are passive, which can under-report the real frequency
of ESAVI in the vaccinated population.
8.6. Risk communication
Although efforts were made to support countries in their risk
communication activities, work remains to be done to strengthen
this important component. Many countries faced a general mis-
trust of the pandemic inﬂuenza (H1N1) vaccine due to widespread
misinformation regarding vaccine safety and the use of adjuvant,
among others. Many rumors began in developed countries and then
spread to LAC countries through the media and social networks.
For the success of future pandemic response efforts, pandemic pre-
paredness plans need to include open and effective communication
strategies to build public conﬁdence and emphasize the importance
of inﬂuenza vaccination.
9.  Next steps
The  ﬁrst inﬂuenza pandemic of the 21st century resulted in
many lessons learned. Globally, LAC was among the regions with
the greatest implementation of pandemic vaccination, despite fac-
ing many challenges. Additional steps must now be taken, at the
national and international levels to ensure that, for the next pan-
demic, low and middle-income countries will have equitable and
timely access to pandemic vaccines and that effective risk commu-
nication strategies will be implemented proactively.
Acknowledgements
First, the authors would like to acknowledge the hard work
and extraordinary dedication of national teams and health workers
responsible for the implementation of pandemic inﬂuenza (H1N1)
vaccination campaigns across Latin America and the Caribbean. The
authors would also like to thank multiple individuals who  con-
tributed to planning and implementation of the pandemic inﬂuenza
vaccination activities at the regional level. From PAHO, Dr. Carlos
Castillo and Ms.  Pamela Bravo provided technical cooperation to
countries in capacity-building for ESAVI surveillance; Ms.  Mon-
ica Pereira managed the operational activities of the Revolving
Fund; Ms.  Bryna Brennan coordinated the work of risk commu-
nication consultants sent to some support national immunization
programs and Dr. Maria de los Angeles Cortes Castillo was involved
in the coordination of regulatory issues with national authorities.
Additionally, the International Development Bank provided funds
which were distributed at the beginning of the pandemic to support
remaining countries to introduce the seasonal inﬂuenza vaccine
and to gain experience in this area in preparation for pandemic vac-
cination; the World Health Organization (WHO) provided technical
support for the sub-regional workshops held to help LAC countries
develop their national inﬂuenza vaccination plans; and Dr. Hector
Izurieta from the Federal Drug Agency (FDA) provided technical
cooperation to strengthen ESAVI surveillance in LAC.
l. / Vac
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[A.M. Ropero-Álvarez et a
eferences
[1] Chan M.  SwChan M.  Swine Inﬂuenza. Geneva: World Health Organization,
April 25, 2009. Available at: http://www.who.int/mediacentre/news/ state-
ments/2009/h1n1 20090425/en/index.html [last accessed 13.06.11].
[2] Chan M.  WoChan M.  World now at the start of inﬂuenza pandemic. Geneva:
World Health Organization, 11 June 2009. Available at: http://www.who.int/
mediacentre/news/statements/2009/h1n1 pandemic phase6 20090611/en/
index.html [last accessed 13.06.11].
[3] World Health Organization. Considerations for assessing the
severity  of an inﬂuenza pandemic. Wkly Epidemiol Rec
2009;84:197–212.  Available at: http://www.http://www.who.int/wer/2009/
wer8422.pdfwho.int/wer/2009/wer8422.pdf [last accessed 13.06.11].
[4] World Health Organization. Strategic Advisory Group of Experts on Immu-
nization – report of the extraordinary meeting on the inﬂuenza A (H1N1)
2009 pandemic, 7 July 2009. Wkly Epidemiol Rec 2009;84:301–8. Avail-
able at: http://www.http://www.who.int/wer/2009/wer8430.pdfwho.int/
wer/2009/wer8430.pdf [last accessed 14.06.11].
[5]  Human infection with pandemic A(H1N1) 2009 inﬂuenza virus: clinical obser-
vations in hospitalized patients, Americas, July 2009 – update. Wkly Epidemiol
Rec 2009;84(30):305–8. Available at: http://www.http://www.who.int/
wer/2009/wer8430.pdfwho.int/wer/2009/wer8430.pdf [last accessed
13.06.11].
[6]  Centers for Disease Control and Prevention. Intensive-care patients with severe
novel inﬂuenza A (H1N1) virus infection – Michigan, June 2009. MMWR  Morb
Mortal Wkly Rep 2009;58(27):749–52.
[7] Creanga A, Johnson T, Graitcer S, Hartman L, Al-Samarrai T, Schwarz A, et al.
Severity of 2009 pandemic inﬂuenza A (H1N1) virus infection in pregnant
women. Obstet Gynecol 2010;115(4):717–26.
[8] Centers for Disease Control and Prevention. 2009 pandemic inﬂuenza A (H1N1)
in pregnant women  requiring intensive care – New York City, 2009. MMWR
Morb Mortal Wkly Rep 2010;59(11):321–6.
[9] World Health Organization. Strategic Advisory Group of Experts
on  Immunization – report of the extraordinary meeting on the
inﬂuenza  A(H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec
2009;84(30):301–4. Available at: http://www.http://www.who.int/wer/2009/
wer8430.pdfwho.int/wer/2009/wer8430.pdf [last accessed 13.06.11].
10] Centers for Disease Control and Prevention. In: Atkinson W,  Hamborsky J, McIn-
tyre L, Wolfe S, editors. Inﬂuenza. Epidemiology and Prevention of Vaccine
– Preventable Diseases. 10th ed. Washington DC: Public Health Foundation;
2008.
11] Nicholson KG, Wood JM,  Zambon M. Inﬂuenza. Lancet
2003;362(9397):1733–45.
12]  World Health Organization. Pandemic inﬂuenza preparedness and
response: a WHO  guidance document. In: Global Inﬂuenza Pro-
gramme. Geneva: World Health Organization; 2009. p. 43. Available at:
http://www.http://www.who.int/csr/disease/inﬂuenza/PIPGuidance09.
pdfwho.int/csr/disease/inﬂuenza/PIPGuidance09.pdf [last accessed 14.06.11].
13]  Pan American Health Organization. Response to Pandemic (H1N1)
2009 in the Americas: Lessons and Challenges, September 2009. Elec-
tronic publication. Available at: http://new.paho.org/hq/index.php?
option=com content&task=blogcategory&id=805&Itemid=569&lang=en
[last  accessed 14.06.11].
14] Tambini G, Andrus JK, Fitzsimmons JW,  Roses Periago M.  Regional immuniza-
tion programs as a model for strengthening cooperation among nations. Rev
Panam Salud Publica 2006;20(1):54–9.
15] DeRoeck D, Bawazir SA, Carrasco P, Kaddar M,  Brooks A, Fitzsimmons J, et al.
Regional group purchasing of vaccines: Review of the Pan American Health
Organization EPI Revolving Fund and the Gulf Cooperation Council group pur-
chasing program. Int J Health Plann Manage 2006;21:23–43.
16] Carrasco P, de Quadros C, Umstead W.  EPI in the Americas: beneﬁts from the
Revolving Fund. WHO  Chron 1983;37:81–5.
17]  World Health Organization: Prevention and control of inﬂuenza pandemics
and annual epidemics. Fifty-Sixth World Health Assembly Resolution 56.19.
http://apps.who.int/gb/archive/pdf ﬁles/WHA56/ea56r19.pdf [last accessed
13.06.11].
18]  World Health Organization: Global pandemic inﬂuenza action plan
to increase vaccine supply. Geneva: World Health Organization,
2006  (WHO/IVB/06.13; WHO/CDS/EPR/GIP/2006.1). Available at:
http://www.who.int/csr/resources/publications/inﬂuenza/WHO CDS EPR GIP
2006 1/en/index.html [last accessed 13.06.11].
19]  Ropero-Álvarez AM,  Kurtis HJ, Danovaro-Holliday MC,  Ruiz-
Matus  C, Andrus JK. Expansion of seasonal inﬂuenza vaccination
[cine 30 (2012) 916– 921 921
in the Americas. BMC  Public Health 2009;9:361–9. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764707/pdf/1471-2458-
9-361.pdf [Last accessed 14.06.11].
20] Pan American Health Organization. Inﬂuenza Pandemic Progress Report: Avail-
able at an Health Organization, Inﬂuenza Pandemic Progress Report: Avail-
able at: http://www.paho.org/french/gov/cd/CD47-inf5-e.pdf [last accessed
13.06.11].
21] World Health Organization: WHO  guidelines on the use of vac-
cines and antivirals during inﬂuenza pandemics. Geneva: World
Health Organization, 2004 (WHO/CDS/CSR/RMD/2004.8) Available at:
http://www.who.int/csr/resources/publications/inﬂuenza/WHO CDS CSR
RMD 2004 8/en/ [last accessed 13.06.11].
22]  World Health Organization: WHO  strategic actions plan for
pandemic inﬂuenza. Geneva: World Health Organization, 2007
(WHO/CDS/EPR/GIP/2006.2a) Available at: http://www.who.int/csr/resources/
publications/inﬂuenza/StregPlanEPR GIP 2006 2 [last accessed 13.06.11].
23] Pan American Health Organization, Technical Guidelines for Vacci-
nation Against the Pandemic Inﬂuenza Vaccine, 2009. Available at:
http://new.paho.org/hq/dmdocuments/2009/IM InﬂuenzaGuidelines
Dec2009 e.pdf [last accessed 13.06.11].
24]  Pan American Health Organization. Technical Advisory Group on
Vaccine-Preventable Diseases. Final Recommendations on Pandemic
Inﬂuenza, 26 August 2009. Available at: http://www.paho.org/english/ad/
fch/im/PandemicFlu TAGReco Aug2009 e.pdf [last accessed 13.06.11].
25] Pan American Health Organization. Surveillance of events suppos-
edly attributable to vaccination or immunization (ESAVI) linked to
the pandemic inﬂuenza (H1N1) 2009 vaccine and crisis preven-
tion:  ﬁeld guide. Washington DC: PAHO Press; 2010. Available at:
http://new.paho.org/hq/index.php?option=com content&task=view&id=2500
&Itemid=2009&lang=en [last accessed 13.06.11].
26]  Pan American Health Organization: UNASUR’s role in the vaccination against
pandemic inﬂuenza. Immunization Newsletter; 2010 XXXII (4). Available at:
http://new.paho.org/hq/index.php?option=com docman&task=doc view&gid
=11624&Itemid=358 [last accessed 13.06.11].
27]  Pan American Health Organization. Emergency Operations Center.
Situation Report 1. Chile Earthquake. Area on Emergency Prepared-
ness and Disaster Relief. Available at: http://new.paho.org/disasters/
index.php?option=com content&task=view&id=1133&Itemid=1036 [last
accessed 13.06.11].
28] Pan American Health Organization. Pandemic (H1N1) 2009 Situation
Reports. Available at: http://new.paho.org/hq/index.php?option=com content
&task=view&id=2527&Itemid=2030&lang=en [last accessed 12.12.11].
29] Siston A, Rasmussen SA, Honein MA,  Fry AM, Seib K, Callaghan WM,  et al. Pan-
demic 2009 inﬂuenza A (H1N1) virus illness among pregnant women in the
United States. JAMA 2010;303(15):1517–25.
30] Australian Government, Department of Health and Aging. Investiga-
tion  into Febrile Convulsions in Young Children after Seasonal Inﬂuenza
Vaccination. Latest ﬁndings and recommendations 30 July 2010.
http://www.health.gov.au/internet/immunise/publishing.nsf/Content/
431453BBFEF1FB2FCA25776D007D9FF4/$File/factsheet-30jul10-V2.pdf [last
accessed 13.06.11].
31] World Health Organization. Global advisory on vaccine safety-narcolepsy.
Statement on narcolepsy and vaccination. 21 April 2011. Available at:
http://www.who.int/vaccine safety/topics/inﬂuenza/pandemic/h1n1 safety
assessing/narcolepsy statement/en/index.html (Last acc (Last accessed on
June 13, 2011).essed on June 13, 2011).
32]  de Oliveira LH, Castillo-Solórzano C, Danovaro-Holliday MC, Pen˜a-Ruz J, Andrus
JK. Vaccine safety. In: Andrus JK, de Quadros CA, editors. Recent advances in
immunization. 2nd ed. Washington DC: PAHO Press; 2006. p. 64–79.
33] Centers for Disease Control and Prevention. Preliminary Results: Surveillance
for Guillain-Barré Syndrome After Receipt of Inﬂuenza A (H1N1) 2009 Mono-
valent Vaccine-United States, 2009–2010. MMWR  Morb Mortal Wkly Rep
2010;59(21):657–61.
34] Landaverde JM,  Danovaro-Holliday MC,  Trumbo SP, Pacis-Tirso CL,
Ruiz-Matus CM.  Guillain-Barré Syndrome in children aged <15 years
in Latin America and the Caribbean: baseline rates in the con-
text  of the inﬂuenza A (H1N1) pandemic. J Infect Dis 2010;201(5):
746–50.35]  Pan American Health Organization. Risk Communication and
Social Mobilization in Support of Vaccination Against Pandemic
Inﬂuenza  in the Americas. Available at: http://new.paho.org/
hq/dmdocuments/2009/H1N1PG AnnexD RiskCommunication.pdf [last
accessed 13.06.11].
